The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy.
R. Geva
No relevant relationships to disclose
B. V. Jensen
No relevant relationships to disclose
G. Fountzilas
No relevant relationships to disclose
T. Yoshino
No relevant relationships to disclose
D. Paez
No relevant relationships to disclose
C. Montagut
No relevant relationships to disclose
I. Sougklakos
Consultant or Advisory Role - Amgen
Honoraria - Merck Serono
F. Cappuzzo
No relevant relationships to disclose
A. Cervantes-Ruiperez
Consultant or Advisory Role - Merck Serono; Roche
Honoraria - Merck Serono
Other Remuneration - Merck Serono
D. Papamichael
No relevant relationships to disclose
M. Frattini
No relevant relationships to disclose
B. Vincenzi
No relevant relationships to disclose
T. Macarulla
No relevant relationships to disclose
F. Loupakis
No relevant relationships to disclose
K. G. Spindler
No relevant relationships to disclose
C. Qvortrup
No relevant relationships to disclose
F. Ciardiello
No relevant relationships to disclose
S. Tejpar
Honoraria - Merck Serono
Research Funding - Merck Serono